title: Treatment with adalimumab for severe immune reconstitution inflammatory syndrome in an HIV-infected patient presenting with cryptococcal meningitis.
authors.affiliation: Service de maladies infectieuses et tropicales, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Gaube
authors.affiliation: Service de maladies infectieuses et tropicales, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: nathalie.de-castro@aphp.fr.
authors.forename: N
authors.initials: N
authors.lastname: De Castro
authors.affiliation: Service de neurologie, fondation ophtalmologique A. de Rothschild, 75019 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Gueguen
authors.affiliation: Service de maladies infectieuses et tropicales, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Lascoux
authors.affiliation: Service de radiologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France.
authors.forename: A-M
authors.initials: AM
authors.lastname: Zagdanski
authors.affiliation: Service de mycologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Université Paris-Diderot Paris 7, 75010 Paris, France; Unité de mycologie moléculaire, centre national de référence mycoses invasives et antifongiques, institut Pasteur, 7CNRS URA3012, 75015 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Alanio
authors.affiliation: Service de maladies infectieuses et tropicales, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot Paris 7, 75010 Paris, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Molina
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines / Q000009:adverse effects / Q000627:therapeutic use; D002163:Cameroon; D003131:Combined Modality Therapy; D003521:Cyclopropanes; D057210:Delayed Diagnosis; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy* / Q000209:etiology; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use; D016919:Meningitis, Cryptococcal / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D017287:Ventriculoperitoneal Shunt
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D014409:Tumor Necrosis Factor-alpha; D019259:Lamivudine; D018119:Stavudine; D000068879:Adalimumab; C098320:efavirenz; D011241:Prednisone
keywords: Cryptococcal meningitis; Cryptococcose méningée; HIV; IRIS; SRI; VIH